Erika P. Hamilton, MD @ErikaHamilton9 @SarahCannonDocs #ESMO20 #breastcancer LIO-1: A Phase 2 study of lucitanib + nivolumab and Initial clinical experience of lucitanib + nivolumab

Erika P. Hamilton, MD Director, Breast Cancer and Gynecologic Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology speaks about ESMO 2020 abstract –

 

·         Initial clinical experience of lucitanib + nivolumab in advanced metastatic solid tumours: data from the phase 1b/2 LIO-1 study (CO-3810-101; NCT04042116)

·         LIO-1: A Phase 2 study of lucitanib + nivolumab in patients (pts) with gynaecological tumours (CO-3810-101; NCT04042116; ENGOT-GYN3/AGO/LIO)